Comparative Pharmacology
Head-to-head clinical analysis: CETACORT versus TEMOVATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETACORT versus TEMOVATE.
CETACORT vs TEMOVATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; binds to glucocorticoid receptors, modulating gene transcription and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit inflammatory mediators (prostaglandins, leukotrienes) and suppress immune response.
1-2 drops or 0.5-1 cm ribbon applied to affected eye(s) 3-4 times daily; for severe inflammation, every 1-2 hours initially. Ophthalmic suspension (0.5% prednisolone acetate) or ointment (0.25% prednisolone acetate).
Apply a thin layer to affected skin areas twice daily (morning and evening). Maximum duration of treatment is 2 consecutive weeks. Do not use more than 50 g per week.
None Documented
None Documented
Terminal half-life: 3.5 hours; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min)
Terminal half-life approximately 36-54 hours, with clinical context indicating prolonged skin retention due to high lipophilicity and slow release from stratum corneum.
Renal: 95% as unchanged drug; biliary/fecal: <5%
Primarily renal; less than 10% as unchanged drug, majority as metabolites. Fecal elimination is minimal (<5%).
Category C
Category C
Topical corticosteroid
Topical corticosteroid